Skip to content
Head to head

Cencora vs McKesson

Side-by-side on the measures that matter, with a plain-English read. Full detail: COR · MCK

Updated 8 minutes ago

1-year performance, rebased to 100

COR -6.5%MCK +25.5%
McKesson edges it on the scoreable measures. McKesson has the highest Quant Rating (72); McKesson has done best over the past year (+26%); McKesson earns the most per share.
CORMCK
Snapshot
SectorMedical Distribution--
Last price339.091,069.43
Change today-0.63%+0.68%
1-year return-5.8%+26.4%
Market cap$64.71B$123.47B
52-week range243.32 – 374.62722.11 – 1,121.50
Valuation
P/E (TTM)18.8927.48
P/E percentile, own 5-yr range28th73rd
P/B17.58-31.23
Dividend yield0.71%0.32%
Profitability & growth
EPS (TTM)17.9538.55
Net profit (TTM)$3.43B$4.45B
Revenue (TTM)$337.40B$418.79B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+5.5%+7.6%
Gross margin4.1%3.7%
Operating margin1.4%1.7%
Net margin1.0%1.1%
Free cash flow (TTM)$3.88B$6.87B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership101.4%89.2%
Insider activity (12mo)31 buy / 17 sell21 buy / 27 sell
Short interest (% of float)1.7%1.7%
Analyst consensus80% buy / 20% hold (10)90% buy / 10% hold (10)
Analyst price target$386 (+14%)$1,211 (+13%)
StockVane view
StockVane Quant RatingD (33)C (72)
Company
Employees51,00043,000
Founded19471833

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.